- Tetrabromobisphenol A Promotes the Osteoclastogenesis of RAW264.7 Cells Induced by Receptor Activator of NF-kappa B Ligand In Vitro
-
Park SY, Choi EM, Suh KS, Kim HS, Chin SO, Rhee SY, Kim DY, Oh S, Chon S
- KMID: 2460925
- J Korean Med Sci.
- 2019 Oct;34(41):e267.
- doi: 10.3346/jkms.2019.34.e267
BACKGROUND: Tetrabromobisphenol A (TBBPA), one of the most widely used brominated flame-retardants, is a representative persistent organic pollutants group. Studies on TBBPA toxicity have been conducted using various target cells;... -
- CITED
-
- Close
- SHARE
-
- Close
- Piperlongumine suppressed osteoclastogenesis in RAW264.7 macrophages
-
Jin SM, Kang HM, Park DB, Yu SB, Kim IR, Park BS
- KMID: 2460804
- Int J Oral Biol.
- 2019 Sep;44(3):89-95.
- doi: 10.11620/IJOB.2019.44.3.89
Piperlongumine (PL) is a natural product found in long pepper (Piper longum). The pharmacological effects of PL are well known, and it has been used for pain, hepatoprotection, and asthma... -
- CITED
-
- Close
- SHARE
-
- Close
- Intravenous Immunoglobulin Controls Th17 Cell-Mediated Osteoclastogenesis
-
Kim KW, Kim HR, Kim BM, Won JY, Lee KA, Lee SH
- KMID: 2455937
- Immune Netw.
- 2019 Aug;19(4):e27.
- doi: 10.4110/in.2019.19.e27
The purpose of this study was to determine the regulatory role of intravenous Ig (IVIg) in Th17 cytokine–induced RANK ligand (RANKL) expression and osteoclast (OC) differentiation from OC precursors (pre-OC).... -
- CITED
-
- Close
- SHARE
-
- Close
- N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis
-
Kim HR, Kim KW, Kim BM, Lee KA, Lee SH
- KMID: 2452505
- Korean J Intern Med.
- 2019 Jan;34(1):210-219.
- doi: 10.3904/kjim.2016.329
BACKGROUND/AIMS: This study aimed to determine the regulatory role of N-acetyl-l-cysteine (NAC), an antioxidant, in interleukin 17 (IL-17)-induced osteoclast differentiation in rheumatoid arthritis (RA). METHODS: After RA synovial fibroblasts were stimulated... -
- CITED
-
- Close
- SHARE
-
- Close
- Propofol promotes osteoclastic bone resorption by increasing DC-STAMP expression
-
Kim EJ, Kim HJ, Baik SW, Kim KH, Ryu SJ, Kim CH, Shin SW
- KMID: 2430212
- J Dent Anesth Pain Med.
- 2018 Dec;18(6):349-359.
- doi: 10.17245/jdapm.2018.18.6.349
BACKGROUND: Propofol is an intravenous anesthetic which has antioxidant effects due to its similarity in molecular structure to α-tocopherol. It has been reported that α-tocopherol increases osteoclast fusion and bone... -
- CITED
-
- Close
- SHARE
-
- Close
- Regulation of Osteoclast Differentiation by Cytokine Networks
-
Amarasekara DS, Yun H, Kim S, Lee N, Kim H, Rho J
- KMID: 2404891
- Immune Netw.
- 2018 Feb;18(1):e8.
- doi: 10.4110/in.2018.18.e8
Cytokines play a pivotal role in maintaining bone homeostasis. Osteoclasts (OCs), the sole bone resorbing cells, are regulated by numerous cytokines. Macrophage colony-stimulating factor and receptor activator of NF-κB ligand... -
- CITED
-
- Close
- SHARE
-
- Close
- Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways
-
Zheng T, Kim NY, Yim M
- KMID: 2397553
- J Bone Metab.
- 2017 Nov;24(4):207-215.
- doi: 10.11005/jbm.2017.24.4.207
BACKGROUND: Osteoclasts are bone resorbing cells and are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Fexaramine has been developed as an agonist for... -
- CITED
-
- Close
- SHARE
-
- Close
- Can denosumab be a substitute, competitor, or complement to bisphosphonates?
-
Kim SY, Ok HG, Birkenmaier C, Kim KH
- KMID: 2376043
- Korean J Pain.
- 2017 Apr;30(2):86-92.
- doi: 10.3344/kjp.2017.30.2.86
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from... -
- CITED
-
- Close
- SHARE
-
- Close
- Denosumab for the treatment of osteoporosis
-
McClung MR
- KMID: 2376998
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):8-17.
- doi: 10.1016/j.afos.2017.01.002
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of... -
- CITED
-
- Close
- SHARE
-
- Close
- Coronary Artery Calcium Score and Bone Metabolism: A Pilot Study in Postmenopausal Women
-
Salari P, Keshtkar A, Shirani S, Mounesan L
- KMID: 2371828
- J Bone Metab.
- 2017 Feb;24(1):15-21.
- doi: 10.11005/jbm.2017.24.1.15
BACKGROUND: Since 1991 many studies evaluated the link between cardiovascular diseases and osteoporosis, two age-related conditions, but the main common pathologic pathway has not been determined yet. The histological similarity... -
- CITED
-
- Close
- SHARE
-
- Close
- Attenuation of RANKL-induced Osteoclast Formation via p38-mediated NFATc1 Signaling Pathways by Extract of Euphorbia Lathyris L
-
Kang JH, Lim H, Jeong JE, Yim M
- KMID: 2361582
- J Bone Metab.
- 2016 Nov;23(4):207-214.
- doi: 10.11005/jbm.2016.23.4.207
BACKGROUND: Osteoclasts are the only cell type capable of breaking down bone matrix, and its excessive activation is responsible for the development of bone-destructive diseases. Euphorbia lathyris L. (ELL) is... -
- CITED
-
- Close
- SHARE
-
- Close
- Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
-
Benjamin B, Benjamin M, Swe M, Sugathan S
- KMID: 2328923
- Osteoporos Sarcopenia.
- 2016 Jun;2(2):77-81.
- doi: 10.1016/j.afos.2016.03.003
OBJECTIVE: Osteoporosis is a rapidly rising cause of concern for elderly patients. Various classes of drugs are available in the market. Bisphosphonates are considered as a first-line therapy for the... -
- CITED
-
- Close
- SHARE
-
- Close
- Osteoclasts: Crucial in Rheumatoid Arthritis
-
Jeong WJ, Kim HJ
- KMID: 2326728
- J Rheum Dis.
- 2016 Jun;23(3):141-147.
- doi: 10.4078/jrd.2016.23.3.141
Osteoclasts are a major component of bone metabolism in physiologic condition and in rheumatoid arthritis (RA). RA is a chronic, autoimmune, inflammatory disease primarily affecting the joints. Joint inflammation leads... -
- CITED
-
- Close
- SHARE
-
- Close
- Hypoxia Inducible Factor-1α Directly Induces the Expression of Receptor Activator of Nuclear Factor-κB Ligand in Chondrocytes
-
Baek K, Park HJ, Baek JH
- KMID: 2162141
- Int J Oral Biol.
- 2016 Mar;41(1):9-15.
- doi: 10.11620/IJOB.2016.41.1.009
Receptor activator of nuclear factor-κB ligand (RANKL) is an osteoblast/stromal cell-derived essential factor for osteoclastogenesis. During endochondral bone formation, hypertrophic chondrocytes calcify cartilage matrix that is subsequently resorbed by osteoclasts... -
- CITED
-
- Close
- SHARE
-
- Close
- Deficiency of Lipocalin-2 Promotes Proliferation and Differentiation of Osteoclast Precursors via Regulation of c-Fms Expression and Nuclear Factor-kappa B Activation
-
Kim HJ, Ohk B, Kang WY, Seong SJ, Suk K, Lim MS, Kim SY, Yoon YR
- KMID: 2156281
- J Bone Metab.
- 2016 Feb;23(1):8-15.
- doi: 10.11005/jbm.2016.23.1.8
BACKGROUND: Lipocalin-2 (LCN2), a small glycoprotein, has a pivotal role in diverse biological processes such as cellular proliferation and differentiation. We previously reported that LCN2 is implicated in osteoclast formation... -
- CITED
-
- Close
- SHARE
-
- Close
- Signaling Pathways in Osteoclast Differentiation
-
Kim JH, Kim N
- KMID: 2152652
- Chonnam Med J.
- 2016 Jan;52(1):12-17.
- doi: 10.4068/cmj.2016.52.1.12
Osteoclasts are multinucleated cells of hematopoietic origin that are responsible for the degradation of old bone matrix. Osteoclast differentiation and activity are controlled by two essential cytokines, macrophage colony-stimulating factor... -
- CITED
-
- Close
- SHARE
-
- Close
- Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells
-
Lee SK, Park KK, Kim KR, Kim HJ, Chung WY
- KMID: 2380881
- J Cancer Prev.
- 2015 Dec;20(4):281-286.
- doi: 10.15430/JCP.2015.20.4.281
Bone destruction induced by the metastasis of breast cancer cells is a frequent complication that is caused by the interaction between cancer cells and bone cells. Receptor activator of nuclear... -
- CITED
-
- Close
- SHARE
-
- Close
- Adseverin mediates RANKL-induced osteoclastogenesis by regulating NFATc1
-
Song MK, Lee ZH, Kim HH
- KMID: 2359886
- Exp Mol Med.
- 2015 Dec;47(12):e199.
- doi: 10.1038/emm.2015.94
Adseverin is a Ca2+-dependent actin filament-severing protein that has been reported to regulate exocytosis via rearrangements of the actin cytoskeleton in secretory cells. However, the role of adseverin in bone... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum amyloid A inhibits RANKL-induced osteoclast formation
-
Oh E, Lee HY, Kim HJ, Park YJ, Seo JK, Park JS, Bae YS
- KMID: 2359881
- Exp Mol Med.
- 2015 Nov;47(11):e194.
- doi: 10.1038/emm.2015.83
When mouse bone marrow-derived macrophages were stimulated with serum amyloid A (SAA), which is a major acute-phase protein, there was strong inhibition of osteoclast formation induced by the receptor activator... -
- CITED
-
- Close
- SHARE
-
- Close
- Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons
-
Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY
- KMID: 2170123
- J Bone Metab.
- 2015 Nov;22(4):151-165.
- doi: 10.11005/jbm.2015.22.4.151
Bisphosphonates are the most widely prescribed drugs for the treatment of osteoporosis, and are also used in malignant bone metastases, multiple myeloma, and Paget's disease, and provide therapeutic efficacy on... -
- CITED
-
- Close
- SHARE
-
- Close
